BerriQi®

MARKET ACCEPTANCE TESTING

BerriQi® 650 mg improves cough, mucus, and respiratory symptoms by 57% over a 4 week period

Anagenix Automated Market Acceptance Testing Platform

14 customers in Malaysia with respiratory symptoms volunteered to try BerriQi® and complete daily symptom questionnaires. Customers reported a number of respiratory triggers. Customers consumed 650 mg of BerriQi® every day for 4 weeks.

Day 0 — Establish Baseline

4 WEEKS — BerriQi 650 mg once daily

The respiratory system faces challenges from pollution, allergens, viruses, and bacteria every day. These stressors can lead to persistent symptoms that reduce the quality of life, even in healthy people. Some of the most common symptoms of persistent respiratory stress are cough, mucus, shortness of breath, and headaches.

BerriQi

MARKET ACCEPTANCE TESTING

Baseline Respiratory Conditions



Customers primarily reported mild and moderate respiratory symptoms prior to beginning BerriQi®. Fewer customers reported chest pain, headaches, and watery eyes.

Symptom severity at screening

Cough
53%

Mucus/Phlegm
51%

Fatigue
46%

Wheezing
41%

Sore Throat
36%



Watery or stinging eyes
33%

Shortness of breath
37%

Headache
26%

Chest pain
23%

BerriQi

MARKET ACCEPTANCE TESTING

BerriQi resulted in
36% – 57%
reduction in respiratory symptoms.

Respiratory symptoms before, during and after 4 weeks of BerriQi consumption.



* % values represent improvement in symptom severity scoring

BerriQi® respiratory health benefits:

- Whole Boysenberry and apple powder
- Contains unique anthocyanins and polyphenols that work in synergy to promote respiratory healing and calm by:
  - Reducing inflammation
  - Reducing mucus production
  - Reducing collagen scarring
- BerriQi® targets a class of immune cells in the lungs called alveolar macrophages, working with your own immune system to restore balance

Percent of customers who recovered from severe cough symptoms compared to baseline



71% customers reported having severe cough symptoms at baseline.

Of these customers, 60% had no symptoms after week 2, and 90% reported no cough symptoms at the end of the 4 week period.

Percent of customers who recovered from severe mucus/phlegm symptoms compared to baseline



71% of the participants reported having severe mucus/phlegm symptoms at baseline.

Of these people, 30% had recovered by week 1, 40% had recovered by week 2, and 90% had recovered by week 4.

Only 14% of customers reported mild symptoms after consuming BerriQi for 4 weeks.

BerriQi

MARKET ACCEPTANCE TESTING

Average symptom scores while consuming BerriQi - 1300 mg dosage



Average symptom scores while consuming BerriQi - 650 mg dosage



There is a clear linkage between dose and symptom recovery. A high dose resulted in better symptom recovery. Chest pain and headache were alleviated more at the higher dose. Additionally, at a higher dose participants recovered quicker. Participants still saw significant improvement at the low dose and could be used as a long term support for symptom recovery.

CONCLUSION:

Customers experience a wide range of respiratory stressors.

Customers experienced a wide range of symptoms before consuming BerriQi.

Customers pursue a wide range of treatments without experiencing much relief.

At a low dose of BerriQi®, the biggest improvements were in cough, mucus, and fatigue.

Customers also reported improvements in shortness of breath, headaches, watery eyes, wheezing, and sore throat.

The largest improvements were seen by Day 14 of BerriQi® consumption, and symptoms continued to improve by Day 28.

BerriQi® effects are dose dependent. For targeted symptom recovery for chest pain and headaches, a higher dose may be more efficacious. A low dose is still effective at symptom reduction.

For more information contact
info@anagenix.com

Anagenix.